Skip to main content
MIRM
NASDAQ Life Sciences

Mirum's Brelovitug Hits AZURE-4 Primary Endpoint, Completing Phase 3 Package for BLA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$93.18
Mkt Cap
$6.083B
52W Low
$63.232
52W High
$130
52W Position info
47% above low
Off High info
28% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

MIRM sits 47% above its 52-week low of $63.232.

Summary

Mirum's brelovitug met the primary endpoint in the Phase 3 AZURE-4 HDV study, with 59% and 44% response rates across the two dose arms versus 0% for delayed treatment. That completes the two-study U.S. registration package, with a BLA planned for the first half of 2027.


Key Events · Product Development and Regulatory · MIRM

  • AZURE-4 Primary Endpoint Met

    At Week 24, 59% of patients on brelovitug 300 mg weekly and 44% on 900 mg every four weeks achieved the combined virologic response plus ALT normalization endpoint, versus 0% in the delayed-treatment arm (p≤0.0001 for both).

  • Second Pivotal Study Completes Package

    AZURE-4 is the second of two Phase 3 studies forming Mirum's U.S. registration package for brelovitug in chronic hepatitis delta virus, following the positive AZURE-1 readout disclosed 2026-09-28.

  • Clean Safety Profile in Sick Population

    No new safety signals were observed; flu-like illness occurred in 17.2% (300 mg QW) and 18.5% (900 mg Q4W) of participants, with injection site reactions in 1.7% and 7.4%. The study enrolled 113 treatment-naive patients, 53% with cirrhosis and mean baseline ALT of 122 U/L.

  • BLA Filing Targeted for First Half 2027

    Mirum plans to submit a Biologics License Application to the FDA in the first half of 2027, with a potential U.S. commercial launch in the fourth quarter of 2027 if approved.


Analysis · MIRM · Life Sciences

AZURE-4 is the second of the two Phase 3 studies that make up brelovitug's U.S. registration package for chronic hepatitis delta virus, so a clean hit here is what turns two positive studies into a filable BLA. The numbers are strong rather than marginal: 59% of patients on 300 mg weekly and 44% on 900 mg every four weeks hit the combined virologic response plus ALT normalization endpoint versus 0% in the delayed-treatment arm, with p≤0.0001 for both. That 0% comparator is the key detail — no delayed-treatment patient responded at all, so the result is not a borderline statistical call. The population was sick (53% cirrhotic, mean baseline ALT 122 U/L), and the drug was well tolerated with no new safety signals. Management now points to a BLA in the first half of 2027 and a potential U.S. launch in Q4 2027. The open question is competitive rather than clinical: HDV is a crowded late-stage field, so launch timing and label breadth will decide how much of the opportunity Mirum actually captures.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MIRM was trading at $93.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $63.23 to $130.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MIRM - Latest Insights

MIRM
Nov 10, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $93.18
Real-time Price: $93.18 info
Change: $0 (0%) info
Market Cap: $6.083B info
MIRM
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $93.18 info
Change: +$6.15 (+7%) info
Market Cap: $6.083B info
MIRM
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $93.18 info
Change: +$6.15 (+7%) info
Market Cap: $6.083B info
MIRM
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $93.18 info
Change: +$6.15 (+7%) info
Market Cap: $6.083B info
MIRM
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $80.15
Real-time Price: $93.18 info
Change: +$13.03 (+16%) info
Market Cap: $6.083B info